Cover Image
市场调查报告书

CNS(中枢神经系统)治疗药市场上最新的开发趋势

Recent Developments in the CNS Drug Market

出版商 BMI Research 商品编码 290257
出版日期 内容信息 英文 76 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
CNS(中枢神经系统)治疗药市场上最新的开发趋势 Recent Developments in the CNS Drug Market
出版日期: 2013年10月29日 内容信息: 英文 76 Pages
简介

神经科学整体市值约为1,453亿美元,由于CNS(中枢神经系统)市场构成其中大部分,该领域还有投资的空间。CNS疾病残留庞大的未满足需求,开发平台治疗药开发维持著稳定成长。

本报告提供全球CNS(中枢神经系统)治疗药市场及近几年的开发趋势相关数据、共同研究,也包含临床实验结果及新产品的认证调查、市场概要、主要企业简介、主要8个治疗领域现在的治疗选项、开发平台等,为您概述为以下内容。

序文

摘要整理

CNS医药品市场

  • 市场概要
  • 主要企业
    • AstraZeneca
    • Biogen Idec
    • Eli Lilly
    • Endo Pharmaceuticals
    • Forest Laboratories
    • GlaxoSmithKline
    • Johnson & Johnson
    • Lundbeck
    • Otsuka
    • Pfizer
    • Purdue Pharma/Mundipharma/Napp Pharmaceuticals
    • Teva

CNS市场部门

  • 疼痛
    • 疼痛的种类
    • 目前疼痛的治疗选项
    • 疼痛开发平台
  • 精神分裂症、躁郁症
    • 目前治疗选项
    • 开发平台
  • 忧郁症
    • 目前治疗选项
    • 开发平台
  • 注意力不足过动症(ADHD)
    • 目前治疗选项
    • 开发平台
  • 癫痫
    • 目前治疗选项
    • 开发平台
  • 多发性硬化症
    • 目前治疗选项
    • 开发平台
  • 老年痴呆症
    • 目前治疗选项
    • 开发平台
  • 帕金森氏症
    • 目前治疗选项
    • 开发平台

参考数据

图表清单

目录
Product Code: RF215

This report reviews the global market for CNS prescription drugs and recent developments within the marketplace, including collaborative agreements, recent clinical trial results and new product approvals across 8 key therapy areas.

Despite recent technological advances, relatively few novel treatments have been launched within the CNS market over the last decade. Many of the current market leaders are beginning to face generic competition or will do within the next five years.

However, the overall neuroscience market is worth approximately US$145.3 billion, and with the CNS market forming a large part of that, there is room for investment to be made. Significant unmet need remains for a number of CNS conditions and the pipeline of drug development remains strong.

This new report from Espicom reviews the recent developments in drug therapy for a number of CNS disorders, providing five-year sales for the current market leaders and forecasts for these and potential therapies to 2020, where available.

Key market questions answered by the report:

  • Who are the current leading players in the CNS drugs market?
  • What are the current treatment options for schizophrenia and bipolar disorder?
  • What are the recent FDA approvals for depression drugs?
  • Which new therapies will increase the value of the multiple sclerosis market?

The Recent Developments in the CNS Drugs Market report is the foolproof business resource for any industry executive that needs to fully understand the current and forecasted CNS market. The need for hard facts and statistics to back up everyday business decisions is essential and it is this report that can provide you with the answers.

What this report contains:

  • Executive Summary
  • The CNS Drugs market overview including the 13 current leading players
  • CNS market sectors breakdown including current treatment options, sales and forecast figures and what's in the pipeline for the following therapy areas:
    • Pain
    • Schizophrenia and Bipolar Disorder
    • Depression
    • Attention Deficit Hyperactivity Disorder (ADHD)
    • Epilepsy
    • Multiple Sclerosis
    • Alzheimer's Disease
    • Parkinson's Disease

Table of Contents

Foreword 1

Executive Summary 3

The CNS Drugs Market 4

  • Market Overview 4
  • The Leading Players 6
    • AstraZeneca 8
    • Biogen Idec 8
    • Eli Lilly 8
    • Endo Pharmaceuticals 8
    • Forest Laboratories 9
    • GlaxoSmithKline 9
    • Johnson & Johnson 9
    • Lundbeck 10
    • Otsuka 10
    • Pfizer 10
    • Purdue Pharma/Mundipharma/Napp Pharmaceuticals 11
    • Shire 11
    • Teva 11

CNS Market Sectors 12

  • Pain 12
    • Types of Pain 12
      • Nociceptive Pain 12
      • Neuropathic Pain 12
      • Psychogenic Pain 13
    • Current Treatment Options for Pain 13
      • Pain Drug Sales and Forecasts 15
      • Neuropathic Pain Management 17
      • The World Health Organization's Pain Ladder 18
    • The Pain Pipeline 18
      • Pipeline Highlights and Recent Developments 21
        • Levadex (dihydroergotamine) 21
        • MoxDuo IR (morphine+oxycodone; Q8003) 22
        • MNK-795 (oxycodone+acetaminophen) 22
        • Posidur (SABER-Bupivacaine) 23
        • Remoxy (oxycodone) 23
        • Zohydro ER (hydrocodone bitartrate) 24
  • Schizophrenia and Bipolar Disorder 25
    • Current Treatment Options for Schizophrenia and Bipolar Disorder 25
      • Schizophrenia Drug Sales and Forecasts 26
    • The Schizophrenia and Bipolar Disorder Pipeline 28
      • Pipeline Highlights and Recent Developments 29
        • Aripiprazole 29
        • Cariprazine 29
        • Fanapt/Fanaptum (iloperidone) 30
  • Depression 31
    • Current Treatment Options for Depression 31
      • Depression Drug Sales and Forecasts 32
      • Recent FDA Approvals for Depression 34
        • Fetzima (levominacipram) 34
        • Brintellix (vortioxentine) 35
    • The Depression Pipeline 37
      • Pipeline Highlights and Recent Developments 38
        • Teva Scraps Nuvigil Development for Depression 38
        • BMS Terminates Development of BMS-820836 for Treatment-resistant Depression 38
  • Attention Deficit Hyperactivity Disorder (ADHD) 39
    • Current Treatment Options for ADHD 39
      • ADHD Drug Sales and Forecasts 40
    • The ADHD Pipeline 43
      • Pipeline Highlights and Recent Developments 43
        • Edivoxetine (LY2216684) 43
        • Metadoxine ER (MG01CI) 44
        • EB-1020 SR Phase IIa Pilot Study Initiated 44
        • Highland Raises Funds to Conduct Studies with Lead Compounds 45
        • Durect and Orient Select Lead Formulation for Oradur-ADHD Programme 45
  • Epilepsy 47
    • Current Treatments for Epilepsy 48
      • Epilepsy Drug Sales and Forecasts 49
    • The Epilepsy Pipeline 50
      • Pipeline Highlights and Recent Developments 51
        • Zebinix (eslicarbazepine) 51
        • Banzel/Inovelon (rufinamide) 52
        • Brivaracetam 52
  • Multiple Sclerosis 54
    • Relapsing Forms of Multiple Sclerosis 54
      • Primary and Secondary Progressive Multiple Sclerosis 54
    • Current Treatments for MS 55
      • Drug Sales and Forecasts 55
    • The MS Pipeline 59
      • Pipeline Highlights and Recent Developments 60
        • Plegridy (peginterferon beta-1a) 60
        • Relonsiv (interferon beta-1b) 60
        • S1P Receptor Agonists 61
        • Arbaclofen 61
        • Sativex for MS Spasticity 62
        • NEU2 Project in Support of Diagnostic for MS 62
  • Alzheimer's Disease 63
    • Current Treatments for AD 63
      • Alzheimer's Disease Drug Sales and Forecasts 63
    • The AD Pipeline 65
      • Pipeline Highlights and Recent Developments 68
        • Diagnosing AD with PET imaging 68
        • Lundbeck and Otsuka development agreement for Lu AE58054 68
        • Fixed-dose combination of memantine ER and donepezil (MDX-8704/ADS-8704) 69
        • Solanezumab 70
        • Gammagard (immunoglobulin) 70
        • Masitinib 71
        • BACE inhibitors 72
        • NNR modulators 73
  • Parkinson's Disease 74
    • Current Treatments for PD 74
      • Parkinson's Disease Drug Sales and Forecasts 75
    • The PD Pipeline 76
      • Pipeline Highlights and Recent Developments 77
        • Dopamine Precursor + DOPA Decarboxylase Inhibitor Combinations 77
        • Adenosine 2A Receptor Inhibition 77
        • Safinamide 78

Sources 80

List of Tables

  • Pain Therapies by Expected US Patent Expiry 13
  • Sales of Leading Pain Management Brands, 2008-2012 (US$ million) 16
  • Sales Forecast for Leading Pain Management Brands, 2014-2020 (US$ million) 17
  • Pain Clinical Pipeline 18
  • Schizophrenia and Bipolar Disorder Therapies by Excepted US Patent Expiry 25
  • Leading Schizophrenia and Bipolar Disorder Therapies by Sales, 2008-2012 (US$ million) 26
  • Sales Forecast for Leading Schizophrenia and Bipolar Disorder Brands, 2014-2020 (US$ million) 27
  • Schizophrenia and Bipolar Disorder Clinical Pipeline 28
  • Depression Therapies by US Patent Expiry 31
  • Leading Anti-depressant Brands by Sales, 2008-2012 (US$ million) 33
  • Sales Forecast for Leading Anti-Depressant Brands, 2014-2020 (US$ million) 33
  • Depression Clinical Pipeline 37
  • ADHD Therapies by US Patent Expiry 40
  • Leading ADHD Brands by Sales, 2008-2012 (US$ million) 41
  • Sales Forecast for Leading ADHD Brands, 2014-2020 (US$ million) 42
  • ADHD Clinical Pipeline 43
  • AEDs by Expected US Patent Expiry 48
  • Leading AEDs by Sales, 2008-2012 (US$ million) 49
  • Sales Forecast for Leading AEDs, 2014-2020 50
  • Epilepsy Clinical Pipeline 51
  • Approved Multiple Sclerosis Therapies 55
  • Multiple Sclerosis Leading Brands by Sales, 2008-2012 (US$ million) 57
  • Multiple Sclerosis Sales Forecast, 2014-2020 (US$ million) 58
  • Multiple Sclerosis Clinical Pipeline 59
  • Approved Alzheimer's Disease Therapies 63
  • Alzheimer's Disease Leading Brands by Sales, 2008-2012 (US$ million) 64
  • Alzheimer's Disease Sales Forecast for Leading Brands, 2014-2020 (US$ million) 65
  • Alzheimer's Disease Clinical Pipeline 67
  • Approved Parkinson's Disease Therapies 74
  • Parkinson's Disease Leading Brands by Sales, 2008-2012 (US$ million) 75
  • Parkinson's Disease Sales Forecast for Leading Brands, 2014-2020 (US$ million) 75
  • Parkinson's Disease Clinical Pipeline 76

List of Figures

  • CNS Market Value by Sector, 2008 (%) 5
  • CNS Market Value by Sector, 2012 (%) 6
  • Leading Companies by Reported CNS Drug Sales, 2012 (%) 7
  • Leading Companies by Forecast CNS Drug Sales, 2017 (%) 7
  • Sales Forecast for Top Five Anti-Depressant Brands, 2014-2020 (US$ million) 34
  • Sales Forecast for Selected ADHD Drugs, 2014-2020 (US$ million) 42
  • Epilepsy Drug Sales Forecast by Company, 2014-2020 (US$ million) 50
  • MS Drug Sales Forecast by Company, 2014-2020 (US$ million) 58
  • Alzheimer's Disease Forecast by Brand, 2014-2020 (US$ million) 65
  • Parkinson's Disease Forecast by Brand, 2014-2020 (US$ million) 76
Back to Top